Xencor (NASDAQ:XNCR) Price Target Raised to $42.00

Xencor (NASDAQ:XNCR) had its price objective increased by Cantor Fitzgerald from $40.00 to $42.00 in a research report report published on Thursday morning, Marketbeat Ratings reports. Cantor Fitzgerald currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other analysts also recently issued reports on the stock. Barclays raised shares of Xencor from an “underweight” rating to an “overweight” rating and raised their price target for the company from $6.00 to $23.00 in a report on Wednesday, October 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research report on Tuesday, October 14th. Royal Bank Of Canada lifted their target price on shares of Xencor from $15.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, October 27th. Bank of America lowered shares of Xencor from a “buy” rating to a “neutral” rating and decreased their target price for the company from $23.00 to $12.00 in a research note on Wednesday, September 3rd. Finally, Wedbush reissued an “outperform” rating and set a $26.00 price target on shares of Xencor in a report on Tuesday, September 2nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.63.

Xencor Price Performance

XNCR stock opened at $13.90 on Thursday. Xencor has a 1-year low of $6.92 and a 1-year high of $27.24. The business has a fifty day moving average price of $11.71 and a 200-day moving average price of $9.69. The stock has a market capitalization of $991.39 million, a P/E ratio of -5.79 and a beta of 0.99.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.72) by $0.64. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%.The company had revenue of $21.00 million for the quarter, compared to analysts’ expectations of $29.73 million. During the same period last year, the firm posted ($0.71) earnings per share. Xencor’s revenue was up 18.0% compared to the same quarter last year. As a group, analysts anticipate that Xencor will post -3.68 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in shares of Xencor during the 1st quarter valued at about $34,000. Hantz Financial Services Inc. increased its holdings in Xencor by 209.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,156 shares in the last quarter. GAMMA Investing LLC raised its stake in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares during the period. CWM LLC lifted its holdings in Xencor by 195.5% during the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company’s stock valued at $36,000 after purchasing an additional 2,231 shares in the last quarter. Finally, Farther Finance Advisors LLC purchased a new position in Xencor during the third quarter valued at approximately $44,000.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.